{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:31:21Z","timestamp":1791592281527,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA249329"],"award-info":[{"award-number":["R01CA249329"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme with numerous roles in DNA damage response signaling, represent a class of anti-cancer drugs approved for treating solid tumors with defects in the DNA damage response. However, additional methods for identifying patients who would benefit from the use of PARP inhibitors are urgently needed. We evaluated a novel radiotracer,\n                      <jats:sup>18<\/jats:sup>\n                      F-FluorThanatrace ([\n                      <jats:sup>18<\/jats:sup>\n                      F]-FTT), to noninvasively assess PARP activity with PET\/CT before treatment and determine associations between uptake, tumor mutation status, and prior receipt of therapy including PARP inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Fifty-two patients with solid tumors underwent whole-body (skull base to thigh) [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FTT PET\/CT scans before beginning PARP inhibitor treatment. The maximum standardized uptake value (SUVmax) was recorded for up to five lesions per patient. All recorded lesions were included in the analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Uptake of [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FTT was confirmed in all 52 patients regardless of primary tumor type (20 breast, 12 ovarian, 7 prostate, 3 pancreas, and 10 other). Lesion-by-lesion analysis revealed significant differences in [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FTT uptake by primary tumor type (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and higher uptake in lesions with\n                      <jats:italic>BRCA2<\/jats:italic>\n                      mutations (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200965) than in lesions with other genetic mutations (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200926) (6.7 vs. 5.5,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03). Prior receipt of PARP inhibitor was associated with lower SUVmax (4.7 vs. 6.4,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001), and prior receipt of systemic therapy was also associated with lower SUVmax (4.0 vs. 6.0,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FTT PET\/CT may be useful as a noninvasive quantitative assessment of PARP1 enzyme activity in patients with solid tumors; uptake of [\n                      <jats:sup>18<\/jats:sup>\n                      F]-FTT varies based on tumor mutational status and receipt of prior PARP inhihbitor therapy and\/or systemic therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-025-07595-3","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:55:02Z","timestamp":1763448902000},"page":"3095-3103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baseline PARP-1 PET imaging in patients with advanced solid tumors with DNA damage response mutations"],"prefix":"10.1007","volume":"53","author":[{"given":"Tarek","family":"Daoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiansong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-8966","authenticated-orcid":false,"given":"Lilie L.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"issue":"7035","key":"7595_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917\u201321.","journal-title":"Nature"},{"issue":"1","key":"7595_CR2","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","volume":"11","author":"L Nguyen","year":"2020","unstructured":"Nguyen L, et al. Pan-cancer landscape of homologous recombination deficiency. Nat Commun. 2020;11(1):5584.","journal-title":"Nat Commun"},{"issue":"23","key":"7595_CR3","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.20.03238","volume":"39","author":"R Casolino","year":"2021","unstructured":"Casolino R, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. J Clin Oncol. 2021;39(23):2617\u201331.","journal-title":"J Clin Oncol"},{"key":"7595_CR4","first-page":"1","volume":"2","author":"AL Heeke","year":"2018","unstructured":"Heeke AL, et al. Prevalence of homologous Recombination-Related gene mutations across multiple cancer types. JCO Precision Oncol. 2018;2:1\u201313.","journal-title":"JCO Precision Oncol"},{"key":"7595_CR5","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1200\/PO.19.00345","volume":"4","author":"ES Sokol","year":"2020","unstructured":"Sokol ES, et al. Pan-Cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by Genome-Wide loss of heterozygosity. JCO Precis Oncol. 2020;4:442\u201365.","journal-title":"JCO Precis Oncol"},{"key":"7595_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.dnarep.2018.08.022","volume":"71","author":"JM Pascal","year":"2018","unstructured":"Pascal JM. The comings and goings of PARP-1 in response to DNA damage. DNA Repair (Amst). 2018;71:177\u201382.","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"7595_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pilie","year":"2019","unstructured":"Pilie PG, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16(2):81\u2013104.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6330","key":"7595_CR8","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152\u20138.","journal-title":"Science"},{"issue":"8","key":"7595_CR9","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.humpath.2013.01.015","volume":"44","author":"A Gan","year":"2013","unstructured":"Gan A, et al. Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival. Hum Pathol. 2013;44(8):1638\u201347.","journal-title":"Hum Pathol"},{"issue":"15","key":"7595_CR10","doi-asserted-by":"publisher","first-page":"4516","DOI":"10.1158\/0008-5472.CAN-16-0416","volume":"76","author":"M Makvandi","year":"2016","unstructured":"Makvandi M, et al. A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP inhibitor therapy. Cancer Res. 2016;76(15):4516\u201324.","journal-title":"Cancer Res"},{"issue":"11","key":"7595_CR11","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"TA Hopkins","year":"2015","unstructured":"Hopkins TA, et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res. 2015;13(11):1465\u201377.","journal-title":"Mol Cancer Res"},{"issue":"5","key":"7595_CR12","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.bmc.2014.01.019","volume":"22","author":"D Zhou","year":"2014","unstructured":"Zhou D, et al. Synthesis, [\u00b9\u2078F] radiolabeling, and evaluation of Poly (ADP-ribose) Polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorg Med Chem. 2014;22(5):1700\u20137.","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"7595_CR13","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1172\/JCI97992","volume":"128","author":"M Makvandi","year":"2018","unstructured":"Makvandi M, et al. A PET imaging agent for evaluating PARP-1 expression in ovarian cancer. J Clin Invest. 2018;128(5):2116\u201326.","journal-title":"J Clin Invest"},{"key":"7595_CR14","doi-asserted-by":"publisher","unstructured":"McDonald ES, et al. In vivo visualization of PARP inhibitor pharmacodynamics. JCI Insight. 2021April 22;6(8). https:\/\/doi.org\/10.1172\/jci.insight.146592.","DOI":"10.1172\/jci.insight.146592"},{"issue":"6","key":"7595_CR15","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1001\/jamaoncol.2020.0334","volume":"6","author":"ES McDonald","year":"2020","unstructured":"McDonald ES, et al. Positron emission tomography imaging of poly\u2013(adenosine diphosphate\u2013ribose) polymerase 1 expression in breast cancer. JAMA Oncol. 2020;6(6):921.","journal-title":"JAMA Oncol"},{"issue":"2","key":"7595_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"key":"7595_CR17","doi-asserted-by":"publisher","first-page":"e2400303","DOI":"10.1200\/PO.24.00303","volume":"8","author":"LL Lin","year":"2024","unstructured":"Lin LL, et al. Pharmacodynamic activity of [(18)F]-Fluorthanatrace Poly(ADP-ribose) polymerase positron emission tomography in patients with BRCA1\/2-Mutated breast cancer receiving Talazoparib. JCO Precis Oncol. 2024;8:e2400303.","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"7595_CR18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s11307-022-01746-w","volume":"24","author":"F Dehdashti","year":"2022","unstructured":"Dehdashti F, et al. Pilot study: PARP1 imaging in advanced prostate cancer. Mol Imaging Biol. 2022;24(6):853\u201361.","journal-title":"Mol Imaging Biol"},{"issue":"32","key":"7595_CR19","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida W, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020;38(32):3763\u201372.","journal-title":"J Clin Oncol"},{"issue":"32","key":"7595_CR20","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1200\/JCO.20.02246","volume":"38","author":"MC Markowski","year":"2020","unstructured":"Markowski MC, Antonarakis ES. BRCA1 versus BRCA2 and PARP inhibitor sensitivity in prostate cancer: more different than alike? J Clin Oncol. 2020;38(32):3735\u20139.","journal-title":"J Clin Oncol"},{"key":"7595_CR21","doi-asserted-by":"crossref","unstructured":"Taza F, et al. Differential activity of PARP inhibitors in BRCA1- versus BRCA2-Altered metastatic castration-resistant prostate cancer. JCO Precis Oncol; 2021. p. 5.","DOI":"10.1200\/PO.21.00070"},{"issue":"1","key":"7595_CR22","first-page":"94","volume":"6","author":"CE Edmonds","year":"2016","unstructured":"Edmonds CE, et al. [(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer. Am J Nucl Med Mol Imaging. 2016;6(1):94\u2013101.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"8","key":"7595_CR23","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1158\/1078-0432.CCR-22-1602","volume":"29","author":"AR Pantel","year":"2023","unstructured":"Pantel AR, et al. [18F]FluorThanatrace ([18F]FTT) PET imaging of PARP-inhibitor drug-target engagement as a biomarker of response in ovarian cancer, a pilot study. Clin Cancer Res. 2023;29(8):1515\u201327. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1602.","journal-title":"Clin Cancer Res."}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07595-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07595-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07595-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T01:26:34Z","timestamp":1774401994000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07595-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7595"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07595-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board and Scientific Review Committee and MD Anderson Cancer Center in Houston, Texas.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients signed informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All patients signed informed consent to participate in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors have the following potential conflicts of interest: LLL reports research support to her institution from Astrazeneca, Pfizer, and Varian. She has received royalty payments from Wolters Kluwer and consulting\/advisory fees from Trevarx and Merck. TAY declares grants or contracts from the following: Acrivon, Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Boundless Bio, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius, F-Star, GlaxoSmithKline, Genentech, Haihe, Ideaya ImmuneSensor, Insilico Medicine, Ionis, Ipsen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Repare, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Tango, Tesaro, Vivace and Zenith. He reports consulting fees from the following: AbbVie, Acrivon, Adagene, Almac, Aduro, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, BioCity Pharma, Blueprint, Boxer, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Diffusion, Duke Street Bio, 858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Kyn, MEI pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus, Novocure, Odyssey, OHSU, OncoSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prolynx, Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Tolremo, Tome, Thryv Therapeutics, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Voronoi Inc, Xinthera, Zai Labs and ZielBio. TAY reports stock in Seagen. FW and PW and JC declare no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}